NCT07516587尚未招募不适用
A Randomized, Double-blind, Placebo-controlled, Crossover Clinical Trial to Investigate the Safety and Efficacy of a Digestive Health Dietary Supplement on Post-meal Bloating in Healthy Participants
Arrae1 个研究点 分布在 1 个国家目标入组 100 人开始时间: 2026年4月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- Mean change in bloating severity from pre-dose to t = 60 minutes post-dose as, comparing active product vs. placebo.
研究概览
简要总结
The goal of this crossover clinical trial is to evaluate the efficacy and safety of Bloat Gummies on postprandial bloating and related gastrointestinal discomfort in healthy adults with recurrent bloating. The main question it aims to answer is whether Bloat gummies reduce post-meal bloating, gas, or abdominal pain (stomach) discomfort. Participants will be asked to consume one dose of Bloat or Placebo after 2 test meals and answer questionnaires on gas, bloating and abdominal distension.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and female individuals aged 18-65 years at time of screening.
- •Body mass index (BMI) <29.9 kg/m².
- •Self-reported recurrent postprandial abdominal bloating and/or distension occurring on average at least 2 days per week over the past 3 months, predominating over other gastrointestinal (GI) symptoms, and in the absence of a diagnosed gastrointestinal disease.
- •Females of child-bearing potential must have a negative baseline pregnancy test and agree to use a medically approved method of birth control for the duration of the study.
- •Willing to consume a standardized test meal consisting of 2 slices of large cheese pizza from Dominos on each test day.
- •Willing to complete online surveys and at-home measurements (waist circumference) at scheduled time points.
- •Agrees to maintain current lifestyle habits (diet, physical activity, medications, supplements, and sleep) as much as possible throughout the study.
- •Provides voluntary, written, informed consent to participate in the study prior to any study procedures.
- •Has reliable access to internet and a smartphone or computer capable of completing electronic surveys and attending virtual check-ins.
排除标准
- •Current or past diagnosis of any significant disease of the GI tract, including but not limited to: irritable bowel syndrome (IBS), celiac disease, inflammatory bowel disease (Crohn's disease or ulcerative colitis), functional constipation, gastroesophageal reflux disease (GERD), gastroparesis, or treatment for H. pylori infection or gastric ulcer within the past year.
- •Significant or untreated medical and/or psychiatric disorders, including but not limited to: severe unstable diabetes, recent myocardial ischemia or infarction, unstable angina, cancer (except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative or volunteers with cancer in full remission for more than five years after diagnosis are acceptable), uncontrolled hypertension, renal failure, chronic active hepatitis, acute hepatitis, cirrhosis, Acquired Immunodeficiency Syndrome (AIDS), malignancy, and neurological disorders including epilepsy, recent cerebrovascular disease, or recent traumatic brain injury.
- •Current use of digestive enzyme supplements, prebiotics/fibers, probiotics, postbiotics, bloating-targeted supplements, therapeutic iron supplementation (>65 mg elemental iron per dose), prokinetic agents, antacids, H2 blockers, proton pump inhibitors (PPIs), opioids, or loperamide within 14 days prior to the first test meal session; or use of any of the above during the study period.
- •Esophageal obstruction or difficulty swallowing.
- •Wear dentures.
- •Pregnant, breastfeeding, or planning to become pregnant during the study.
- •Known allergy, or sensitivity to any ingredient of the study supplement or placebo, including ginger, lemon balm, dandelion, or Bifidobacterium longum-derived products.
- •Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of standardized meal ingredients.
- •Alcohol use disorder or drug abuse/dependence within the past 6 months (>2 standard drinks/day on average).
- •Currently following an extremely restrictive diet or having done so within the past 3 months.
- •Participation in another clinical research trial within 30 days prior to randomization.
- •Cognitively impaired or unable to provide informed consent.
- •Any other condition that, in the Investigator's opinion, may adversely affect the participant's ability to complete the study or its measures, or that may pose significant risk to the participant.
研究组 & 干预措施
Bloat Gummy
Experimental
Bloat is a gummy that contains the active ingredients ginger root extract, lemon balm extract, dandelion root extract and the postbiotic HTES1, Bifidobacterium longum CECT7347.
干预措施: Bloat Gummies (Dietary Supplement)
Placebo Gummy
Placebo Comparator
The placebo is a gummy that looks and tastes like the study gummy, but with no active ingredients.
干预措施: Placebo (Dietary Supplement)
结局指标
主要结局
Mean change in bloating severity from pre-dose to t = 60 minutes post-dose as, comparing active product vs. placebo.
时间窗: Evaluated from pre-dose to 60 minutes post-dose
Bloating severity assessed by Bloating Likert Scale of 0 to 4, with 0 being "no symptoms" and 4 being "severe symptoms."
次要结局
- Mean change in bloating severity from pre-dose to t = 30 minutes post-dose, comparing active product vs placebo.(Evaluated from pre-dose to 30 minutes post-dose)
- Mean change in abdominal discomfort severity from pre-dose to t = 30 and 60 minutes post-dose, comparing active product vs. placebo.(Evaluated from pre-dose to 30 and 60 minutes post-dose.)
- Mean change in waist circumference from pre-dose to t = 30 and t = 60 minutes post-dose, comparing active product vs. placebo.(Evaluated from pre-dose to 30 and 60 minutes post-dose.)
- Proportion of participants demonstrating a reduction in waist circumference.(Evaluated at 30 minutes, 60. minutes or both timepoints post-dose.)
- Mean change in gas severity from pre-dose to t = 30 and 60 minutes post-dose, comparing active product vs. placebo.(Evaluated from pre-dose to 30 and 60 minutes post-dose.)
- Proportion of participants demonstrating a reduction in waist circumference.(Evaluated at 30 minutes, 60 minutes or both timepoints post-dose.)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
Phase 3 4
Efficacy of Metaberine® on Postprandial Blood Glucose in Prediabetic IndividualsCTRI/2025/08/093675ZeusHygia LifeSciences Private Ltd36
招募中
2 期
Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory Latency Time (IELT), Patient-Reported Outcomes, and Safety in Men With Lifelong Premature Ejaculation (LPE)Premature EjaculationNCT07434271Kadence Bio40
尚未招募
不适用
A Clinical Study to Assess the Safety and Efficacy of Scalp Cream in patients with DandruffCTRI/2025/07/090946Blossom Microbiotics LLC34
尚未招募
3 期
Clinical Study to evaluate the Efficacy and Safety of a Dose for Soreness in reducing Muscle Soreness and improving muscle relaxationCTRI/2024/05/068070Eetho Brands70
尚未招募
2 期
Trial of Tirzepatide for the Treatment of Cannabis Use DisorderNCT07468552National Institute on Drug Abuse (NIDA)100